Table 4.
Serum free light chain response evaluation and relapse anticipation from treatment line one to four and of the study cohort.
| Therapy | First Line | Second Line | Third Line | Fourth Line | Cohort | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Involved pre-FLC | <138 mg/mL | 28 | 9 (32) | 41 | 14 (34) | 71 | 33 (46) | 55 | 25 (45) | 195 | 82 (42) |
| ≥138 mg/mL | 19 (68) | 27 (66) | 38 (54) | 30 (55) | 113 (58) | ||||||
| Pre-FLCr | <25 | 28 | 10 (36) | 41 | 23 (56) | 71 | 39 (55) | 55 | 33 (60) | 195 | 105 (54) |
| ≥25 | 18 (64) | 18 (44) | 32 (45) | 22 (40) | 90 (46) | ||||||
| Involved post-FLC | <138 mg/mL | 41 | 14 (34) | 71 | 33 (46) | 68 | 26 (38) | 49 | 19 (39) | 229 | 93 (41) |
| ≥138 mg/mL | 27 (66) | 38 (54) | 42 (62) | 30 (61) | 136 (59) | ||||||
| Post-FLCr | <25 | 41 | 23 (56) | 71 | 39 (55) | 68 | 36 (56) | 49 | 26 (53) | 229 | 124 (55) |
| ≥25 | 18 (44) | 32 (45) | 32 (44) | 23 (47) | 105 (45) | ||||||
| First sFLC alteration | <6 months | 12 | 9 (75) | 18 | 11 (61) | 26 | 16 (62) | 24 | 19 (79) | 80 | 55 (69) |
| 6–12 months | 2 (17) | 7 (39) | 9 (35) | 4 (17) | 22 (27) | ||||||
| >12 months | 1 (8) | 0 | 1 (3) | 1 (4) | 3 (4) | ||||||
| Anticipation sFLC type | No alteration | 17 | 5 (29) | 35 | 17 (48) | 34 | 8 (24) | 29 | 5 (17) | 115 | 35 (30) |
| sFLC + M-Pr. | 8 (47) | 7 (20) | 17 (50) | 13 (45) | 45 (40) | ||||||
| sFLC alone | 4 (24) | 11 (32) | 9 (26) | 11 (38) | 35 (30) | ||||||
Abbreviations: Involved pre-FLC—involved serum free light chains prior to treatment start; Pre-FLCr—serum free light chains ratio prior to treatment start; Involved post-FLC—involved serum free light chains at disease relapse following last therapy; Post-FLCr—serum free light chains ratio at disease relapse following last therapy; sFLC – serum free light chains; M-Pr.—monoclonal protein.